You have 8 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Daratumumab

Showing 51 - 75 of 273
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Myeloma in Relapse Trial in Paris (Daratumumab/Lenalidomide/Dexamethasone for 24 months,

Recruiting
  • Multiple Myeloma in Relapse
  • Daratumumab/Lenalidomide/Dexamethasone for 24 months
  • Daratumumab/Lenalidomide/Dexamethasone until progression
  • Paris, France
    Saint Antoine Hospital - Hematology Department
Jun 10, 2022

Multiple Myeloma Trial in Germany (Teclistamab (Tec), Daratumumab, Dexamethasone)

Recruiting
  • Multiple Myeloma
  • Teclistamab (Tec)
  • +4 more
  • Berlin, Germany
  • +8 more
Jan 19, 2023

Multiple Myeloma Trial in United States (TTI-622, Daratumumab Hyaluronidase-fihj)

Recruiting
  • Multiple Myeloma
  • TTI-622
  • Daratumumab Hyaluronidase-fihj
  • Basking Ridge, New Jersey
  • +6 more
Dec 8, 2022

Amyloidosis; Systemic Trial in Beijing (Daratumumab, Bortezomib, Dexamethasone)

Active, not recruiting
  • Amyloidosis; Systemic
  • Daratumumab
  • +2 more
  • Beijing, China
    Peking Union Medical College Hospital
May 9, 2022

Multiple Myeloma, Relapsed Cancer, Refractory Multiple Myeloma Trial (ANV419, Lenalidomide with low-dose dexamethasone,

Not yet recruiting
  • Multiple Myeloma
  • +4 more
  • (no location specified)
Nov 29, 2022

Multiple Myeloma Trial (89Zr-DFO-daratumumab, PET/CT)

Withdrawn
  • Multiple Myeloma
  • (no location specified)
Jun 30, 2022

Bladder Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma, Malignant Urinary System Tumor Trial in Houston (procedure,

Active, not recruiting
  • Bladder Urothelial Carcinoma
  • +4 more
  • Biopsy
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 18, 2022

Relapsed or Refractory Multiple Myeloma Trial (Daratumumab, Pomalidomide)

Withdrawn
  • Relapsed or Refractory Multiple Myeloma
  • (no location specified)
Jan 26, 2023

AL Amyloidosis Trial in Beijing

Recruiting
  • AL Amyloidosis
    • Beijing, China
      Peking Union Medical College Hospital
    Apr 20, 2022

    Plasma Cell Myeloma Trial in Rochester (Bortezomib, Daratumumab, Dexamethasone)

    Recruiting
    • Plasma Cell Myeloma
    • Rochester, Minnesota
      Mayo Clinic in Rochester
    Jan 4, 2023

    Multiple Myeloma Trial in Adelaide, Melbourne, Oslo (XmAb24306, Daratumumab)

    Recruiting
    • Multiple Myeloma
    • Adelaide, South Australia, Australia
    • +2 more
    Aug 1, 2022

    Antibody-mediated Rejection, Cardiac Transplant Trial in Rochester (Daratumumab and hyaluronidase-fihj)

    Enrolling by invitation
    • Antibody-mediated Rejection
    • Cardiac Transplant
    • Daratumumab and hyaluronidase-fihj
    • Rochester, Minnesota
      Mayo Clinic Rochester
    Apr 11, 2022

    Multiple Myeloma Trial in Worldwide (Daratumumab Subcutaneous (SC) Administration, Recombinant Human Hyaluronidase [rHuPH20]) SC

    Active, not recruiting
    • Multiple Myeloma
    • Daratumumab Subcutaneous (SC) Administration
    • Recombinant Human Hyaluronidase [rHuPH20]) SC Administration
    • Atlanta, Georgia
    • +11 more
    Aug 11, 2022

    Multiple Myeloma Trial in Rochester (Daratumumab, Lenalidomide, Dexamethasone)

    Recruiting
    • Multiple Myeloma
    • Daratumumab
    • +2 more
    • Rochester, New York
      University of Rochester Medical Center
    Jul 8, 2022

    Multiple Myeloma, Multiple Myeloma in Relapse, Tumors Trial (Belantamab Mafodotin-Blmf, Daratumumab, Pomalidomide)

    Not yet recruiting
    • Multiple Myeloma
    • +8 more
    • Belantamab Mafodotin-Blmf
    • +3 more
    • (no location specified)
    Oct 13, 2022

    Nephrotic Syndrome Trial in Genova (Rituximab Biosimilar ABP 798, Daratumumab)

    Not yet recruiting
    • Nephrotic Syndrome
    • Rituximab Biosimilar ABP 798
    • Daratumumab
    • Genova, Italy
      IRCCS G. Gaslini
    Jan 19, 2023

    Multiple Myeloma Trial in Baltimore (Ciforadenant, daratumumab)

    Completed
    • Multiple Myeloma
    • Baltimore, Maryland
      The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Mar 9, 2022

    Plasma Cell Myeloma Trial in Jacksonville (procedure, biological, drug)

    Active, not recruiting
    • Plasma Cell Myeloma
    • Autologous Hematopoietic Stem Cell Transplantation
    • +2 more
    • Jacksonville, Florida
      Mayo Clinic in Florida
    Mar 25, 2022

    Multiple Myeloma Trial in Torino (Velcade, Melphalan, Prednisone)

    Recruiting
    • Multiple Myeloma
    • Torino, TO, Italy
      Dipartimento di Biotecnologie Molecolari e Scienze per la Salute
    May 25, 2022

    Antibody-mediated Rejection, Kidney Tranplant Trial in Hangzhou (Daratumumab)

    Not yet recruiting
    • Antibody-mediated Rejection
    • Kidney Tranplant
    • Daratumumab
    • Hangzhou, Zhejiang, China
      79# Qingchun Road
    Jun 21, 2023

    Plasma Cell Myeloma Trial in Rochester (biological, drug, other)

    Active, not recruiting
    • Plasma Cell Myeloma
    • Daratumumab
    • +5 more
    • Rochester, Minnesota
      Mayo Clinic
    Sep 8, 2022

    Multiple Myeloma Trial in Amsterdam (all-trans retinoic acid (ATRA))

    Active, not recruiting
    • Multiple Myeloma
    • all-trans retinoic acid (ATRA)
    • Amsterdam, NH, Netherlands
      VU University Medical Center
    May 5, 2022

    Relapsed or Refractory Multiple Myeloma Trial (Forimtamig, Carfilzomib, Daratumumab)

    Not yet recruiting
    • Relapsed or Refractory Multiple Myeloma
    • (no location specified)
    Sep 20, 2023

    Chronic Lymphocytic Leukemia Trial in Columbus (biological, drug, other)

    Recruiting
    • Chronic Lymphocytic Leukemia
    • Daratumumab
    • +3 more
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    Feb 24, 2022

    Multiple Myeloma Trial in Germany, Greece (Daratumumab, Bortezomib, Dexamethasone)

    Completed
    • Multiple Myeloma
    • Daratumumab
    • +2 more
    • Berlin, Germany
    • +9 more
    May 27, 2022